The use of new russian beta-2-agonist salgim in dry powder form for inhalations in bronchial asthma patients

Abstract

Forty patients with mild to moderate bronchial asthma were treated with the new β₂-agonist Salgim. Basic active components of this drug are salbutamol hemisuccinate and natrium benzoate. Salgim was used in dry powder form placed in cyclohaler for inhalations. The drug compared with Salgim was Bricanyl (salbutamol sulfate in powder form), placed in turbuhaler. The data obtained in this study have persuasively demonstrated that this drug form possesses a high broncholytic activity throughout bronchi. Strong expectorative activity of Salgim greatly increases its clinical efficacy in patients with broncho-obstructive syndrome. A treatment course with Salgim allowes to control reliably a bronchial passability in mild bronchial asthma patients and combined with other anti-asthmatic drugs - in moderate asthmatic patients. The protective action of Salgim was studied. It was shown that Salgim has broncho-protective activity. The side effects of Salgim do not exceed the limits of selective β₂-agonists. Concerning its clinical efficacy Salgim is not inferior to the foreign selective β₂-agonist Bricanyl ("Astra” , Sweden).